Abstract

Peritoneum is a common site of colorectal tumor metastasis. Patients with colorectal cancer who are diagnosed with peritoneum metastasis have extremely bad prognosis. Traditionally, peritoneum metastasis is regarded as a distant metastasis of colorectal cancer and classified as IV stage, which can only receive palliative treatment. However, more and more specialists gradually consider simple peritoneal carcinomatosis as a local regional disease, thus more aggressive treatment modality can be adopted, including cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Multiple clinical trials have verified combination of CRS and HIPEC can dramatically improve prognosis and overall survival of patients compared to palliative surgery and systematic chemotherapy. However, the absence of a unified criterion for patients selection and treatment protocol gets in the way of the application of HIPEC, which still needs many clinical trials to make a standard guideline. Key words: Colorectal neoplasms; Neoplasm metastasis; Peritoneal carcinomatosis; Hyperthermic intraperitoneal chemotherapy; Cytoreductive surgery

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.